BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25431423)

  • 1. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
    El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
    Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
    Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.
    Vitucci M; Karpinich NO; Bash RE; Werneke AM; Schmid RS; White KK; McNeill RS; Huff B; Wang S; Van Dyke T; Miller CR
    Neuro Oncol; 2013 Oct; 15(10):1317-29. PubMed ID: 23814263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
    Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
    Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
    Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG
    Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
    Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
    PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.
    Gürsel DB; Connell-Albert YS; Tuskan RG; Anastassiadis T; Walrath JC; Hawes JJ; Amlin-Van Schaick JC; Reilly KM
    Neuro Oncol; 2011 Jun; 13(6):610-21. PubMed ID: 21636709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.
    Zhao HF; Wang J; Jiang HR; Chen ZP; To SS
    J Exp Clin Cancer Res; 2016 May; 35():78. PubMed ID: 27176481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
    Prasad G; Sottero T; Yang X; Mueller S; James CD; Weiss WA; Polley MY; Ozawa T; Berger MS; Aftab DT; Prados MD; Haas-Kogan DA
    Neuro Oncol; 2011 Apr; 13(4):384-92. PubMed ID: 21317208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
    Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
    J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.
    Guo T; Wu C; Zhang J; Yu J; Li G; Jiang H; Zhang X; Yu R; Liu X
    Cell Commun Signal; 2023 Dec; 21(1):363. PubMed ID: 38115126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K/AKT signaling pathway.
    Cheng Y; Xie P
    J Biochem Mol Toxicol; 2019 Nov; 33(11):e22392. PubMed ID: 31503386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
    Wu S; Wang S; Gao F; Li L; Zheng S; Yung WKA; Koul D
    Neuro Oncol; 2018 Jan; 20(1):78-91. PubMed ID: 29016926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational Orthotopic Models of Glioblastoma Multiforme.
    El Meskini R; Atkinson D; Weaver Ohler Z
    J Vis Exp; 2023 Feb; (192):. PubMed ID: 36876943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
    Carra E; Barbieri F; Marubbi D; Pattarozzi A; Favoni RE; Florio T; Daga A
    Cell Cycle; 2013 Feb; 12(3):491-500. PubMed ID: 23324350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.